Tenaya Therapeutics Inc (TNYA) - Net Assets
Based on the latest financial reports, Tenaya Therapeutics Inc (TNYA) has net assets worth $82.87 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($104.98 Million) and total liabilities ($22.11 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible net worth ratio of Tenaya Therapeutics Inc to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $82.87 Million |
| % of Total Assets | 78.94% |
| Annual Growth Rate | N/A |
| 5-Year Change | -33.41% |
| 10-Year Change | N/A |
| Growth Volatility | 57.05 |
Tenaya Therapeutics Inc - Net Assets Trend (2019–2024)
This chart illustrates how Tenaya Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. See Tenaya Therapeutics Inc (TNYA) liquidity interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Tenaya Therapeutics Inc (2019–2024)
The table below shows the annual net assets of Tenaya Therapeutics Inc from 2019 to 2024. For live valuation and market cap data, see Tenaya Therapeutics Inc (TNYA) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $92.85 Million | -33.40% |
| 2023-12-31 | $139.42 Million | -42.71% |
| 2022-12-31 | $243.38 Million | -12.62% |
| 2021-12-31 | $278.53 Million | +99.75% |
| 2020-12-31 | $139.44 Million | +418.80% |
| 2019-12-31 | $-43.74 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Tenaya Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 46999400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $8.00K | 0.01% |
| Other Comprehensive Income | $28.00K | 0.03% |
| Other Components | $607.23 Million | 653.96% |
| Total Equity | $92.85 Million | 100.00% |
Tenaya Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Tenaya Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Finbar Group Ltd
AU:FRI
|
$136.71 Million |
|
SHL Consolidated Bhd
KLSE:6017
|
$136.78 Million |
|
Bionime Corp
TW:4737
|
$136.84 Million |
|
Kyochon F And B Co Ltd
KO:339770
|
$136.85 Million |
|
First Farms A/S
CO:FFARMS
|
$136.64 Million |
|
Dwi Guna Laksana Tbk PT
JK:DWGL
|
$136.63 Million |
|
SR Bancorp, Inc. Common stock
NASDAQ:SRBK
|
$136.63 Million |
|
Chosun Refractories Co Ltd
KO:000480
|
$136.58 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tenaya Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 139,424,000 to 92,854,000, a change of -46,570,000 (-33.4%).
- Net loss of 111,129,000 reduced equity.
- New share issuances of 46,762,000 increased equity.
- Other comprehensive income increased equity by 134,000.
- Other factors increased equity by 17,663,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-111.13 Million | -119.68% |
| Share Issuances | $46.76 Million | +50.36% |
| Other Comprehensive Income | $134.00K | +0.14% |
| Other Changes | $17.66 Million | +19.02% |
| Total Change | $- | -33.40% |
Book Value vs Market Value Analysis
This analysis compares Tenaya Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.65x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-1.61 | $0.71 | x |
| 2020-12-31 | $3.39 | $0.71 | x |
| 2021-12-31 | $6.75 | $0.71 | x |
| 2022-12-31 | $5.43 | $0.71 | x |
| 2023-12-31 | $1.89 | $0.71 | x |
| 2024-12-31 | $1.09 | $0.71 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tenaya Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -119.68%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.29x
- Recent ROE (-119.68%) is below the historical average (-52.01%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-21.40 Million |
| 2020 | -27.54% | 0.00% | 0.00x | 1.06x | $-52.34 Million |
| 2021 | -25.01% | 0.00% | 0.00x | 1.14x | $-97.50 Million |
| 2022 | -50.81% | 0.00% | 0.00x | 1.15x | $-148.00 Million |
| 2023 | -89.00% | 0.00% | 0.00x | 1.22x | $-138.03 Million |
| 2024 | -119.68% | 0.00% | 0.00x | 1.29x | $-120.41 Million |
Industry Comparison
This section compares Tenaya Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tenaya Therapeutics Inc (TNYA) | $82.87 Million | 0.00% | 0.27x | $136.66 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Tenaya Therapeutics Inc
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. The company's lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in phase 2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ve… Read more